Guardant Health Gestione

Gestione criteri di controllo 4/4

Guardant Health Il CEO è Helmy Eltoukhy, nominato in Jan2013, e ha un mandato di 11.83 anni. la retribuzione annua totale è $ 11.59K, composta da 0.01% di stipendio e 100% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.13% delle azioni della società, per un valore di € 78.34M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.5 anni e 3.2 anni.

Informazioni chiave

Helmy Eltoukhy

Amministratore delegato

US$11.6k

Compenso totale

Percentuale dello stipendio del CEO	0.009%
Mandato del CEO	11.8yrs
Proprietà del CEO	2.1%
Durata media del management	3.5yrs
Durata media del Consiglio di amministrazione	3.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Helmy Eltoukhy rispetto agli utili di Guardant Health?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$512m
Jun 30 2024	n/a	n/a	-US$491m
Mar 31 2024	n/a	n/a	-US$461m
Dec 31 2023	US$12k	US$1	-US$479m
Sep 30 2023	n/a	n/a	-US$432m
Jun 30 2023	n/a	n/a	-US$508m
Mar 31 2023	n/a	n/a	-US$665m
Dec 31 2022	US$12k	US$1	-US$655m
Sep 30 2022	n/a	n/a	-US$606m
Jun 30 2022	n/a	n/a	-US$551m
Mar 31 2022	n/a	n/a	-US$419m
Dec 31 2021	US$14k	US$1	-US$406m
Sep 30 2021	n/a	n/a	-US$409m
Jun 30 2021	n/a	n/a	-US$379m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$114m	US$210k	-US$254m
Sep 30 2020	n/a	n/a	-US$185m
Jun 30 2020	n/a	n/a	-US$120m
Mar 31 2020	n/a	n/a	-US$77m
Dec 31 2019	US$915k	US$500k	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	n/a	n/a	-US$87m
Mar 31 2019	n/a	n/a	-US$97m
Dec 31 2018	US$818k	US$480k	-US$85m
Sep 30 2018	n/a	n/a	-US$75m
Jun 30 2018	n/a	n/a	-US$84m
Mar 31 2018	n/a	n/a	-US$83m
Dec 31 2017	US$4m	US$460k	-US$89m

Compensazione vs Mercato: La retribuzione totale di Helmy ($USD 11.59K ) è inferiore alla media delle aziende di dimensioni simili nel mercato German ($USD 1.90M ).

Compensazione vs guadagni: La retribuzione di Helmy è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Helmy Eltoukhy (45 yo)

11.8yrs

Mandato

US$11,591

Compensazione

Dr. Helmy Eltoukhy, Ph D., is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC.Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health,...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Helmy Eltoukhy	Co-Founder	11.8yrs	US$11.59k	2.13% € 78.3m
AmirAli Talasaz	Co-CEO & Director	3.3yrs	US$26.42k	2.2% € 81.0m
Michael Bell	Chief Financial Officer	3.8yrs	US$4.12m	0.019% € 716.4k
Darya Chudova	Chief Technology Officer	no data	US$4.76m	0.044% € 1.6m
Craig Eagle	Chief Medical Officer	3.5yrs	US$3.49m	0.019% € 692.1k
Christopher Freeman	Chief Commercial Officer	3.4yrs	US$3.52m	0.025% € 935.8k
Kumud Kalia	Chief Information Officer	4.8yrs	Nessun dato	0.014% € 527.8k
Zarak Khurshid	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
John Saia	Chief Legal Officer & Corporate Secretary	4.5yrs	US$6.02m	0.027% € 980.3k
Jennifer Higgins	Senior Vice President of Public Affairs	no data	Nessun dato	Nessun dato
Stephen Murphy	Senior Vice President of Marketing	less than a year	Nessun dato	Nessun dato
Terilyn Monroe	Chief People Officer	less than a year	Nessun dato	Nessun dato

3.5yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di 5GH è considerato esperto (durata media dell'incarico 3.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Helmy Eltoukhy	Co-Founder	11.8yrs	US$11.59k	2.13% € 78.3m
AmirAli Talasaz	Co-CEO & Director	11.8yrs	US$26.42k	2.2% € 81.0m
Myrtle Potter	Independent Director	3.1yrs	US$425.21k	0.011% € 406.2k
Ian T. Clark	Lead Independent Director	7.8yrs	US$470.21k	0.0068% € 251.1k
Roberto Mignone	Director	less than a year	Nessun dato	Nessun dato
Steve Krognes	Independent Director	2.4yrs	US$425.21k	0.0080% € 294.8k
Musa Tariq	Independent Director	1.7yrs	US$725.30k	0.0040% € 148.5k
Vijaya Gadde	Independent Director	4.4yrs	US$425.21k	0.014% € 524.9k
Meghan Joyce	Independent Director	3.3yrs	US$425.21k	0.0062% € 227.5k
Manuel Medina	Director	less than a year	Nessun dato	Nessun dato

3.2yrs

Durata media

50.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 5GH sono considerati esperti (durata media dell'incarico 3.2 anni).

Guardant Health Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

High number of new directors

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Management Changes

Recent updates

Now 22% undervalued

Third quarter 2024 earnings released: US$0.88 loss per share (vs US$0.73 loss in 3Q 2023)

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Second quarter 2024 earnings released: US$0.84 loss per share (vs US$0.67 loss in 2Q 2023)

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

New major risk - Share price stability

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

High number of new directors

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.94 loss per share (vs US$1.30 loss in 1Q 2023)

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Share price stability

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Full year 2023 earnings released: US$4.28 loss per share (vs US$6.41 loss in FY 2022)

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Guardant Health, Inc. to Appeal Federal District Court Verdict

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$1.58 loss in 3Q 2022)

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Now 20% undervalued after recent price drop

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$2.25 loss in 2Q 2022)

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in 1Q 2022)

Guardant Health, Inc. Announces Management Changes

High number of new directors

Co-CEO & Director recently bought €2.3m worth of stock

Chief Information Officer recently sold €182k worth of stock

Full year 2022 earnings released: US$6.41 loss per share (vs US$4.00 loss in FY 2021)

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer

Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy

Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer

Chief Information Officer recently sold €156k worth of stock

Third quarter 2022 earnings released: US$1.58 loss per share (vs US$1.06 loss in 3Q 2021)

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients

Senior Vice President of People recently sold €212k worth of stock

Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations